Phase 4Status unknownAge-related condition
Clinical Study of PCSK9 Inhibitors for Preventing Early Neurological Deterioration in Branch Atheromatous Disease
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Enrolment
- 76 planned
- Conditions
- Acute Ischemic Stroke
- Interventions
- Evolocumab 140 mg subcutaneously combined with Rosuvastatin 20 mg orally; Rosuvastatin 20 mg orally
- Ages
- adults, older adults
- Registry
- ChiCTR2600130261
Full record on the Chinese Clinical Trial RegistrySource: WHO ICTRP, processed 24 August 2026
Primary outcomes
- Incidence of Early Neurological Deterioration (END) and incidence of Severe Early Neurological Deterioration (SEND)
- Lipid attainment rate (Day 7, Day 30);
History
Last registry update
Started
Registered